MedTrace Logo

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis

NCT03010527 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 217

Last updated 2022-10-18

Study results available
· View outcomes & findings →

Summary

This is a multicenter extension study to assess the long-term safety, tolerability and efficacy of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis

Conditions

  • Chronic Plaque Psoriasis

Interventions

DRUG

Bimekizumab

Subjects will receive bimekizumab injections every four weeks (Q4W)

OTHER

Placebo

Subjects will receive Placebo injections every four weeks (Q4W)

Sponsors & Collaborators

  • UCB Biopharma SRL

    lead INDUSTRY

Principal Investigators

  • UCB Cares · 001 844 599 2273 (UCB)

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-14
Primary Completion
2018-09-25
Completion
2018-09-25
FDA Drug
Yes

Countries

  • United States
  • Canada
  • Czechia
  • Hungary
  • Japan
  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03010527 on ClinicalTrials.gov